Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Oak Hill Bio","sponsor":"Chiesi Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chiesi Group and Oak Hill Bio Announce License and Development Agreement to Develop, Manufacture, and Commercialise OHB-607, a Potentially Transformative Neonatal Therapy","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Oak Hill Bio","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oak Hill Bio & Chiesi Group Resume Phase 2 Study of OHB-607 for Bronchopulmonary Dysplasia","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"May 2024","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Oak Hill Bio

    Menu

    Oak Hill Bio

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Oak Hill Bio

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Oak Hill Bio & Chiesi Group Resume Phase 2 Study of OHB-607 for Bronchopulmonary Dysplasia

              Details:

              OHB-607 is the recombinant form of human insulin-like growth factor-1 (IGF-1). It is being evaluated for the prevention of bronchopulmonary dysplasia in premature infants.

              Lead Product(s): Mecasermin Rinfabate

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: OHB-607

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Chiesi Group

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 17, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Oak Hill Bio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Chiesi Group and Oak Hill Bio Announce License and Development Agreement to Develop, Manufacture, and Commercialise OHB-607, a Potentially Transformative Neonatal Therapy

              Details:

              The agreement aims to develop, manufacture, and commercialise OHB-607 (mecasermin rinfabate), a recombinant version of insulin-like growth factor-1 (IGF-1), being developed to treat complications of extremely premature birth.

              Lead Product(s): Mecasermin Rinfabate

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: OHB-607

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Chiesi Group

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement January 09, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY